Elevation Oncology Announces Promising Initial Data from Phase 1 Clinical Trial Evaluating EO-3021 in Patients with Advanced Unresectable or Metastatic Solid Tumors Likely to Express Claudin 18.2

Stock Information for Elevation Oncology Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Elevation Oncology Inc.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FLS, ELEV, MTWO, CRKN on Behalf of Shareholders
HAPPY FATHER'S DAY! and $HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Elevation Oncology, Inc. (NASDAQ: ELEV) 
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CRKN, ELEV, STR, VIGL on Behalf of Shareholders
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Crown Electrokinetics Corp. (OTC - CRKN), Elevation Oncology, Inc. (Nasdaq - ELEV), Sitio Royalties Corp. (NYSE - STR), Vigil Neuroscience, Inc. (Nasdaq - VIGL)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates KNW, ELEV, CRKN on Behalf of Shareholders
ELEVATION ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Elevation Oncology, Inc. - ELEV
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FLS, KNW, ELEV, CRKN on Behalf of Shareholders
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Crown Electrokinetics Corp. (OTC - CRKN), Elevation Oncology, Inc. (Nasdaq - ELEV), Sitio Royalties Corp. (NYSE - STR), Vigil Neuroscience, Inc. (Nasdaq - VIGL)

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.